CD274 and neoplasm: Numerous successful clinical trials have led to a great number of FDA approvals for PD-1/PD-L1 blockade therapy in a spectrum of different tumour types: melanoma, non-small cell lung cancer, urothelial carcinoma, classic Hodgkin lymphoma, renal cell carcinoma, Merkel cell carcinoma, hepatocellular carcinoma, gastric carcinomas, and head and neck squamous cell carcinoma.